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P-glycoprotein (P-gp) is a 170 kDa membrane glycoprotein which
exports a number of structurally and functionally unrelated drugs
from the cell, decreases intracellular accumulation of these drugs,
and thus, causes the phenomenon of multidrug resistance (MDR)
(Bosch and Croop, 1996). P-gp has been detected in a variety of
human cancers, including osteosarcoma, and may be at least
partially responsible for the observed drug resistance in some
current chemotherapy regimens (Chan et al, 1991; Balidini et al,
1995).
There has been recent interest in changes in tumour cell pheno-
type in relation to P-gp expression. For example, studies on human
neuroblastoma and mouse sarcoma cell lines have shown that
increased expression of P-gp correlates with a decrease in onco-
genic activity and expression of a more differentiated phenotype
(Bielder, 1994; Bielder and Spengler, 1994). Similar results have
been obtained in a variety of MDR cell lines. Furthermore, a trans-
fection study of MDR1 gene in osteosarcoma cells clearly demon-
strated a cause-effect relationship between P-gp expression and a
less aggressive phenotype (Scotlandi et al, 1999). In contrast,
studies on rat liver carcinogenesis have consistently indicated an
association of P-gp overexpression with tumour progression
(Bradley et al, 1992; Bradley and Ling, 1994). In an immunohisto-
chemical analysis of human colon cancer, P-gp was overexpressed
in relation to the increased invasiveness of tumour cells (Weinstein
et al, 1991). It thus appears that although P-gp may play a role in
reduced malignancy, observed phenotypic changes do not always
reflect the function of P-gp.
We recently isolated several clones of a murine osteosarcoma
by pulse exposures of the parental cells to doxorubicin (DOX)
followed by single-cell culture (Takeshita et al, 1996). Many of
these single-cell clones overexpressed P-gp, but some clones did
not express detectable P-gp. The P-gp-positive clones displayed a
relatively low level of resistance similar to clinically observed
drug resistance, and retained tumorigenic activity, and thus,
appeared to be a useful model for additional investigations into
MDR osteosarcoma (Takeshita et al, 1998). In the present study,
we further characterized these P-gp-positive and P-gp-negative
osteosarcoma clones, and found that DOX-selected osteosarcoma
cells express osteoblastic differentiation and a low aggressive
phenotype, regardless of their P-gp status.
MATERIALS AND METHODS
Cell lines
Two P-gp-positive (MOS/ADR1 and MOS/ADR2) and two P-gp-
negative (MOS/RV1 and MOS/RV2) single-cell clones as well as
the parent osteosarcoma cell line were used for the present study.
These clones were selected by exposure to DOX, as described
previously (Takeshita et al, 1996). The MOS/ADR1 and
MOS/RV1 cells consisted of non-polyploid cells having DNA
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consisted of polyploid cells. The cell lines were maintained at
37°C in a humidified incubator containing 5% carbon dioxide in
Dulbecco’s modified Eagle medium supplemented with 15 mmol
l–1 HEPES buffer, 10% fetal calf serum and an antibiotic solution.
P-gp expression and cellular DNA content
Cells grown on coverslips were washed with phosphate-buffered
saline (PBS), fixed with acetone for 30 min, and stained by the
indirect immunofluorescence method. The primary monoclonal
antibody C219 (Centcor Diagnostics, USA) was applied for 20 h
at 4°C (5 µg ml–1). After washing with PBS, the cells were incu-
bated with fluorescein isothiocyanate (FITC)-conjugated F (ab)´2
goat anti-mouse IgG (Caltag Laboratories, USA) for 1 h and
rewashed with PBS. P-gp immunofluorescence was examined
with a fluorescence microscope. For the DNA content analysis,
cells were harvested by trypsinization, smeared onto glass slides
with a cyto-tec centrifuge, fixed with 70% ethanol, treated with
0.1% RNAase and then stained with propidium iodide. The
cellular DNA content was measured by cytofluorometry.
MDR phenotype
MDR phenotype of the cell lines was determined using the MTT
(3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide)
assay described by Hansen et al (1989). IC50 values (concentra-
tions of the drugs that produce 50% growth inhibition) were deter-
mined for each of the cell lines.
Cellular alkaline phosphatase (ALP) activity
Cells were harvested by trypsinization, suspended in 10 mmol 1–1
Tris–hydrochloride (pH 7.4) containing 1 mmol 1–1 magnesium
chloride, 20 mmol l–1 zinc chloride, 0.02% (weight per volume)
sodium azide and 0.1% Triton X-100, and sonicated for 30 s. The
sonicates were centrifuged for 15 min at 8000 g at 4°C. ALP
activity was determined by measuring spectrophotometrically
(410 nm at 37°C) the release of p-nitrophenol from p-nitro-
phenylphosphatase using the method of Lowry (1955). Protein
was measured using a protein assay kit (BCA; Pierce, USA).
Fluorescent staining of cellular actin
Cells grown on coverslips were rinsed briefly in PBS, fixed for
5 min with buffered formalin and then washed with PBS. The cells
were then permeabilized by a 2-min exposure to 0.1% Triton
X-100 in PBS at room temperature, followed by rinsing with PBS.
FITC-conjugated phalloidin (Sigma; Wulf et al, 1979) was applied
to the cells at a concentration of 0.05 mg ml–1 in PBS, and was
allowed to react for 40 min in a humid atmosphere. After washing
with PBS, the cells were examined by a fluorescence microscope.
In vivo tumour growth
After the cells were trypsinized, 1 ´ 107 cells in a small volume of
medium was injected subcutaneously (s.c.) in C3H/Sed mice. The
tumours were measured weekly in two perpendicular dimensions
until their volumes exceeded 2000 mm3. The tumour volumes
were estimated using the formula (a2 ´ b)/2, where a is the shorter
and b is the longer of the two measurements. The primary tumours
in s.c. and both lungs were then resected. One half of each tumour
was cultured for the study of P-gp staining. The other half of the
tumour and lungs were fixed with buffered formalin, and then
processed for histological examination. Lung metastases of the
tumour cells were assessed using both macroscopic and micro-
scopic findings of the lung specimens.
RESULTS
P-gp expression and MDR phenotype in clonal cell
lines
Compared with the parent cell line, the P-gp-positive lines,
MOS/ADR1 and MOS/ADR2, were more resistant to DOX,
vincristine and etoposide, all of which are known to be substrates
for P-gp (Table 1). In contrast, the P-gp-negative lines, MOS/RV1
and MOS/RV2 were not resistant to these drugs. All cell lines
displayed similar sensitivity to methotrexate, which is not a
substrate for P-gp. There was no relationship between P-gp
expression and cellular polyploidization. Considering that these
subclones were all isolated from the surviving cells after exposure
of the parent cells to DOX, the P-gp-negative single cell clones
appeared to be composed of revertants of P-gp-positive cells.
Indeed, we confirmed that P-gp-mediated drug-resistant pheno-
type was rapidly lost in DOX-free medium, using a DOX accumu-
lation assay for colony-forming cells (data not shown).
Differentiation of the DOX-treated osteosarcoma clones
Both the P-gp-positive and P-gp-negative clones demonstrated
higher ALP activity than the parent cell line (Figure 1).
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Table 1 Pgp expression, DNA content and MDR phenotype
IC50 (mg ml–1)
Cell line P-gpa DI DOX VCR ETP MTX
MOS –b 1.4 0.022 (1)d 0.0049 (1) 0.065 (1) 0.022 (1)
MOS/RV1 – 1.3 0.011 (0.5) 0.0023 (0.46) 0.061 (0.93) 0.018 (0.81)
MOS/RV2 – 2.5 0.035 (1.5) 0.0023 (0.46) 0.095 (1.4) 0.010 (0.45)
MOS/ADR1 +c 1.3 0.16 (7.2) 0.074 (15) 0.28 (4.3) 0.017 (0.77)
MOS/ADR1 + 2.4 0.41 (18) 0.060 (12) 0.85 (13) 0.025 (1.1)
aP-gp, P-glycoprotein; DI, DNA index; DOX, doxorubicin; VCR, vincristine; ETP, etoposide; MTX, methotrexate. b–, Pgp was not stained positively with mAb
C219. c+, More than 50% of cells were stained positively with mAb C219. dNumbers in parentheses represent relative values as compared with the IC50 for the
parent MOS cells.Morphologically, these clones were characterized by the presence
of those cells which had well-organized actin stress fibres in their
cytoplasm. In the parent cells, however, the actin fibres were either
sparsely distributed or diffusely spread throughout the cytoplasm
(Figure 2 A–E). Although all the tumours produced by inoculation
of cultured cells into mice s.c. exhibited histological characteris-
tics of osteogenic sarcoma, they varied in cellularity and the
amount of bone and osteoid matrix (Figure 2 F–J). The tumours
resulting from inoculation of the parent cells consisted of dense
tumour cells with a small amount of relatively immature osteoid
formation. The tumours produced from inoculation of the
MOS/ADR1 cells showed more abundant bone and osteoid forma-
tion than those produced by the parent cell line. Similar histo-
logical findings were observed in the tumours produced from the
MOS/ADR2 cells or the MOS/RV1 cells. The tumours produced
by the MOS/RV2 cells revealed relatively higher cellularity.
In vivo tumour growth and metastatic potential
The parent osteosarcoma cell line (MOS) showed 100% tumori-
genicity following a s.c. injection of these cultured cells into mice,
all of which developed metastatic lesions in the lungs (Table 2). In
mice inoculated with the MOS cells, the tumours grew rapidly
with a doubling time of 4.9 days. In contrast, all four subclones,
which were isolated after exposure of the parent cells to DOX,
demonstrated a decrease in tumorigenicity, growth rate and
metastatic potential. No mice inoculated with these subclones
developed metastases in the lungs.
DISCUSSION
Recent investigations have shown that adverse prognosis in
P-gp overexpressing osteosarcomas may result simply from resis-
tance to chemotherapy, but not from biological aggressiveness
(Scotlandi et al, 1996). In fact, studies of MDR1gene-transfected
osteosarcoma cells demonstrated that P-gp may have a direct or at
least an indirect role in a decrease in aggressive tumour phenotype
(Scotlandi et al, 1999). In the present study, we characterized the
P-gp-positive and P-gp-negative single-cell clones of a murine
osteosarcoma, to further investigate the relationship between P-gp
expression and the observed changes in cell phenotype.
Our results demonstrated that the P-gp-positive MDR clones
and P-gp-negative drug-sensitive clones both expressed more
differentiated and less aggressive tumour phenotype, when
compared to the parent osteosarcoma cells. These clones exhibited
enhanced activity of cellular alkaline phosphatase, an increase in
well-organized actin stress fibres and enhanced osteogenic
activity. Moreover, they all displayed a decrease in oncogenic
activity, tumour growth rate and metastatic ability, regardless of
their P-gp status. Regarding these observations, two different
explanations can be discussed.
Because the osteosarcoma subclones described here were all
isolated from the surviving cells following DOX exposure, the
P-gp-negative, drug-sensitive clones appeared to be composed of
revertants of P-gp overexpressing cells. Based on this hypothesis,
it is possible that the reduced malignancy found in the P-gp-
positive and P-gp-negative clones may be due to an indirect effect
of P-gp. In this case, as pointed out by Scotlandi, expression of the
MDR1gene may result in coactivation of other genes responsible
for the decreased malignancy, and then, only the MDR1gene
expression was partially suppressed in the P-gp-negative
clones.
Another possible explanation may be that DOX produced a
significant effect on osteoblastic differentiation and a decrease in
aggressive phenotype both in the P-gp-positive and P-gp-negative
clones, although P-gp also played a role in reduced malignancy
in the P-gp-positive clones. Unlike MDR1gene transfectants
(Scotlandi et al, 1999), our panel of osteosarcoma subclones
selected by DOX showed morphological and functional changes in
their cellular differentiative state. Moreover, DOX is known to
promote cellular differentiation (Morceau et al, 1996). Thus,
consideration of the effect of DOX, as well as P-gp, appeared to be
more relevant to explain our experimental results.
Although our results were obtained from only one model of
MDR osteosarcoma, they might help to explain the divergent find-
ings regarding the relationship between P-gp expression and
malignancy. It is known that MDR1gene expression can be
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Figure 1Cellular ALP activity determined by the method of Lowly. The data
were representative of two independent experiments with similar results. The
results are expressed as µmol min–1 mg–1 protein. Bars, standard deviation
Table 2doubling time and metastatic ability a
Cell line n Tumour (%) Doubling time (day) Metastases (%)
MOS 12 12/12 (100) 4.9 12/12 (100)
MOS/RV1 12 3/12 (25) 15.0 0/12 (0)
MOS/RV2 12 8/12 (66) 7.9 0/12 (0)
MOS/ADR1 12 7/12 (58) 10.0 0/12 (0)
MOS/ADR2 12 6/12 (50) 11.8 0/12 (0)
aTumorigenicity and metastatic ability are shown as a total of two independent experiments with similar results. In each
experiment, cells (1 ´107) were injected into six mice, and tumour growth was monitored until 3 months after injection.
Doubling times represent means of two to six determinations in the experiment 21330 H Takeshita et al






Figure 2 Fluorescent staining of cellular actin by FITC-conjugated phalloidin (A–E) (magnification ´ 1000), and haematoxylin and eosin staining of histological
sections of tumours in mice (F–J) (magnification ´ 40). A and F, parent cell line. B and G, MOS/RV1. C and H, MOS/RV2. D and I, MOS/ADR1. E and J,
MOS/ADR2stimulated by a broad spectrum of structurally and functionally
unrelated agents, including anticancer drugs (Fardel et al, 1997),
differentiation-inducing agents (Mickerley et al, 1989), growth
factors (Hirsch-Ernst et al, 1995), carcinogens (Fairchild et al,
1987), tumour necrosis factor alpha (Hirsch-Ernst et al, 1998), and
UV-irradiations (Uchiumi at al, 1993). All these agents may be
able to cause P-gp overproduction as well as their known effects in
a cell. In addition, P-gp itself is also likely to have positive effects
on a decrease in aggressive phenotype. Therefore, the combined
effects of all these factors should be taken into consideration. For
example, the use of an anticancer drug for selection of MDR cells
is expected to result in coexpression of P-gp and the reduced
malignant phenotype, because the drug and P-gp may both
suppress aggressive phenotype. In contrast, when MDR1 gene
expression is stimulated by carcinogens or by growth factors, P-gp
expression may be associated with either more aggressive or less
aggressive tumour phenotype depending on the total effects of
these factors and P-gp. It is also possible that several factors
having different actions may simultaneously stimulate MDR1 gene
expression. Moreover, cell phenotype expression might be affected
by the tissue origin of the cell. To prove these hypotheses,
however, further studies using various stimulators of MDR1 gene
expression as well as different types of cells are needed.
In conclusion, we demonstrated that both the P-gp-positive and
P-gp-negative osteosarcoma clones selected by DOX exposure
expressed osteoblastic differentiation and less aggressive tumour
phenotype. It is known from clinical studies that human osteosar-
coma cells often appear to exhibit histological differentiation after
drug treatment (Jaffe, 1993; Link, 1993), and to express a high
level of P-gp in the relapsed tumours (Serra et al, 1995). Studies
are underway to determine the relationship between P-gp-
mediated MDR and differentiation in a clinical setting.
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